DEB-TACE vs Conventional TACE in Intermediate HCC: Best Candidates for DEB-TACE?
|
|
- Gabriel Harris
- 5 years ago
- Views:
Transcription
1 DEB-TACE vs Conventional TACE in Intermediate HCC: Best Candidates for DEB-TACE? Ho Jong Chun, MD., PhD Seoul St. Mary s Hospital, The Catholic University of Korea
2 Why Drug-eluting Beads? Clear Rationale - Maximize drug delivery - Consistent/better reproducibility of the method - Long-lasting effect/slow release - Lower systemic side effect
3 DC Beads TM Comparison with Intraarterial Injection in Rabbit Hong K et al. Clin Cancer Res 2006;12:
4 DC Beads TM Pharmacokinetics Varela M et al.j Hepatol Mar;46(3):474-81
5 DEB-TACE Possible Advantages over c-tace Localized delivery of drugs Controlled/sustained release of drugs More chemotherapeutic agent in the tumor higher tumor objective response Less chemotherapeutic agent in blood stream less systemic toxicity or adverse effect
6 Seoul St. Mary s Hospital Typical Imaging Course on CT Pre Cone beam CT after TACE 1 day 1 month 3 month contrast saturation
7 DEB-TACE vs ctace RCT (2010) p = 0.11 Lammer J et al. CVIR 2010;33:41-52
8 DEB-TACE vs ctace RCT (2010) DC Bead showed significant advantage in patients with negative prognostic factors Patients for with objective negative response prognostic (p=0.038) factors and disease control (p=0.026) Lammer J et al. CVIR 2010;33:41-52
9 DEB-TACE vs ctace RCT (2014) 177 patients RCT (Precision Italia Study Group) DEB-TACE (n=89) vs ctace (n=88) 1- and 2-year survival (p=0.949) % and 56.8% after DEB-TACE % and 55.4% after ctace Objective tumor response (p>0.05) R Golfieri, et al. British Journal of Cancer 2014;111:
10 DEB-TACE vs ctace RCT (2014) Adverse events Subgroup analysis R Golfieri, et al. British Journal of Cancer 2014;111:
11 DEB-TACE vs ctace Meta-analysis (2014) Objective tumor response for DEB-TACE Huang K, et al. J Gastroenterol Hepatol. 2014;29:
12 DEB-TACE vs ctace Meta-analysis (2014) Disease control for DEB-TACE Complications for DEB-TACE Han S, et al. PLoS One 2014;9(8):e102686
13 DEB-TACE vs ctace Meta-analysis (2015) Overall survival Objective tumor response Xie Z, et al. Hepatology Research 2015;45:
14 DEB-TACE vs ctace Pathologic Comparison (2014) 111 consecutive HCC before OLT DEB-TACE (n=35) vs ctace (n=76) Complete necrosis after OLT % for ctace % for DEB-TACE No significant differences of necrosis rate, tumor recurrence, drop-out and tolerability. Frenette CT, et al. Transplantation. 2014;987:
15 DEB-TACE vs ctace Summary Two RCTs, Three Meta-anaslysis, One Pathologic Comparison Tumor response DEB-TACE ctace Survival DEB-TACE ctace Safety DEB-TACE ctace
16 DEB-TACE vs ctace Embolization Characteristics DEB-TACE ctace material PVA microsphere Lipiodol+gelfoam duration permanent transient vessel damage severe mild size 100~300 μm liquid level catheter technique only within or just before tumor avoid wedge the catheter (catheter<feeding artery) can pass thru portal vein can wedge the catheter (catheter feeding artery)
17 Predictive Factors for Complete Response after DEB-TACE 172 patients with 315 tumors Imaging response evaluation with mrecist 1 month after DEB-TACE Tumor size > 5 cm CR Median location (S1/S4) CR common intrahepatic collaterals & anastomosis Total extinction blush CR Vesselle G, et al. Eur Radiol Oct 11
18 Predictive Factors for Histologic Necrosis after DEB-TACE 23 patients with 27 tumors within Milan criteria Imaging response evaluation with mrecist Explant pathology comparison after DEB-TACE Odisio BC, et al. CVIR 2014;37:
19 Predictive Factors for Histologic Necrosis after DEB-TACE 23 patients with 27 tumors within Milan criteria Imaging response evaluation with mrecist Explant pathology comparison after DEB-TACE Mean overall initial lesion diameter (p=0.030) - group 1 (> 50% necrosis) 3.2 cm - group 2 ( 50% necrosis) 2.1 cm Presence of capsule (p=0.0027) - group 1 (> 50% necrosis) 78% - group 2 ( 50% necrosis) 22% Odisio BC, et al. CVIR 2014;37:
20 Predictive Factors for Histologic Necrosis after DEB-TACE 23 patients with 27 tumors within Milan criteria Imaging response evaluation with mrecist Explant pathology comparison after DEB-TACE Mean overall initial lesion diameter (p=0.030) - group 1 (> 50% necrosis) 3.2 cm - group 2 ( 50% necrosis) 2.1 cm Presence of capsule (p=0.0027) - group 1 (> 50% necrosis) 78% - group 2 ( 50% necrosis) 22% Smaller (<2 cm) and non-encapsulated tumor necrosis Odisio BC, et al. CVIR 2014;37:
21 Predictive Factors for Histologic Necrosis after DEB-TACE 61 patients before OLT Explant pathology comparison after DEB-TACE Smaller (<2 cm) and non-encapsulated tumor necrosis Fasarella PM, et al. CIRSE 2015
22 Small HCCs M/61 HCC(B)/Child A Two small HCCs: ~1.5 cm, probably encapsulated, some hypervascular Peripheral location, fine feeding arteries
23 Small HCCs M/61 HCC(B)/Child A Two small HCCs: ~1.5 cm, probably encapsulated, some hypervascular Peripheral location, fine feeding arteries DEB-TACE ( μm+doxorubicin 50 mg)
24 Small HCCs M/61 HCC(B)/Child A Two small HCCs: ~1.5 cm, probably encapsulated, some hypervascular Peripheral location, fine feeding arteries DEB-TACE ( μm+doxorubicin 50 mg) CR/SD on 1 month FU
25 Small HCCs M/75 HCC(B)/Child A/Recurrent nodule after TACE small HCC: 1.3 cm probably encapsulated hypervascular one feeding artery less than catheter diameter wedging the catheter
26 Small HCCs M/75 HCC(B)/Child A/Recurrent nodule after TACE small HCC: 1.3 cm probably encapsulated hypervascular one feeding artery less than catheter diameter wedging the catheter limited in DEB TACE due to smaller feeding artery than the microcatheter early or proximal plugging
27 DEB-TACE Small HCCs vs Intermediate/Large HCCs 90 patients with HCCs (n=119) Imaging response evaluation with mrecist 1 month follow-up after DEB-TACE Size # CR PR SD PD 2 cm (68%) 5 (10%) 11 (22%) 0 (0%) > 2 cm 5 cm (67.3%) 12 (23.1%) 4 (7.7) 1 (1.9%) > 5 cm 17 7 (41.2%) 9 (53%) 1 (5.8%) 0 (0%) P= > 5 cm tumor was significantly lower in CR than 5 cm tumor on 1 month FU after DEB TACE. Subgroup analysis from Oh JS, Chun HJ, et al. J Vasc Interv Radiol 2013; 24:
28 DEB-TACE Small HCCs vs Intermediate/Large HCCs 90 patients with HCCs (n=119) Imaging response evaluation with mrecist 1 month follow-up after DEB-TACE Size # OR SD PD 2 cm (78%) 11 (22%) 0 (0%) > 2 cm 5 cm 52 47(90.4%) 4 (7.7) 1 (1.9%) > 5 cm (94.2%) 1 (5.8%) 0 (0%) P= > 5 cm tumor was significantly lower in CR than 5 cm tumor on 1 month FU after DEB TACE. 2 cm tumor was significantly lower in OR than > 2 cm tumor. Subgroup analysis from Oh JS, Chun HJ, et al. J Vasc Interv Radiol 2013; 24:
29 Better Response Factors for DEB-TACE 1. Tumor size Smaller < Intermediate/Large
30 Better Response Factors for DEB-TACE 1. Tumor size Smaller < Intermediate/Large 2. Tumor location
31 Central/Median lobe HCCs M/57 HCC(B)/Child A Single intermediate-size HCC: ~4.1 cm, encapsulated, hypervascular Central location, multiple fine feeding arteries only segmental treatment (DEB-TACE)
32 Central/Median lobe HCCs M/57 HCC(B)/Child A Single intermediate-size HCC: ~4.1 cm, encapsulated, hypervascular Central location, multiple fine feeding arteries only segmental treatment (DEB-TACE) PR on 1 month FU feeding artery damage limited in repeated TACE
33 Central/Median lobe HCCs M/83 HCC(B)/Child A Multiple HCCs: ~3.8 cm, encapsulated, hypervascular Central location, multiple fine feeding arteries only lobar treatment
34 Central/Median lobe HCCs M/83 HCC(B)/Child A Multiple HCCs: ~3.8 cm, encapsulated, hypervascular Central location, multiple fine feeding arteries only lobar treatment limited in DEB-TACE due to mandatory lobar treatment for multiple/central HCC
35 Better Response Factors for DEB-TACE 1. Tumor size Smaller < Intermediate/Large 2. Tumor location Median/central < Peripheral/subcapsular
36 Better Response Factors for DEB-TACE 1. Tumor size Smaller < Intermediate/Large 2. Tumor location Median/central < Peripheral/subcapsular 3. Tumor vascularity - Enhancement degree on CT/MR - Angiographic staining degree - Perfusion volume on CT/DSA - Diffuse-weighted MR (DWMR)
37 Predictors for Response after DEB-TACE on DWMR 57 patients with HCCs Diffuse-weighed MR (DWMR) study before/after DEB-TACE Imaging response evaluation with mrecist Low ADC value High cellularity/non-necrosis/high vascularity At baseline, lesions with OR at 1 and 3 months showed more restricted diffusion compared with others (p=0.031) A baseline ADC < mm 2 /s is a predictor of survival. Kokabi N, et al. J Vasc Interv Radiol 2015;26:
38 Better Response Factors for DEB-TACE 1. Tumor size Smaller < Intermediate/Large 2. Tumor location Median/central < Peripheral/subcapsular 3. Tumor vascularity Hypervascular 4. Can be treated with superselective approach
39 DEB-TACE vs ctace Liver/Biliary Injury 237 patients with NET (n=134), HCC (n=103) CT/ MR evaluation after ctace (n=294), DEB-TACE (n=182) DEB-TACE is independently associated with liver/biliary injuries (OR=6.62). Biloma/parenchymal infarct strongly associated with DEB-TACE (OR=9.78;p=0.002) and underlying noncirrhotic liver (OR=8.13;p=0.04). Guiu B, et al. Journal of Hepatology 2012;56:
40 DEB-TACE ctace Limitations of DEB-TACE 1. Limited embolization effect in small HCC - Difficulty to target the tumor/small feeding artery - Weak arterial supply/large portal vein flow supply 2. Limited in hypovascular tumor TACE 3. Limited in non-superselective embolization - More parenchymal/bile duct damage - Non-feeding artery damage/early feeding artery occlusion 4. Limited in repeated TACE - Feeding artery permanent occlusion/damage
41 Previous Suggested Indications of DEB-TACE Patients with heart problem (Excellent pharmacokinetics) Patients with advanced clinical stage (Better tumor response) Patients with larger tumor (Excellent pharmacokinetics) Same with ctace Non-resectable tumor Down-stage or bridge for surgery Recurrent tumor after surgery Better tumor response Early detection of residual/recurrent tumor prolonged overall survival
42 Current Suggested Indications of DEB-TACE Think the advantages - Excellent pharmacokinetics - Less post-embolization syndrome - Better tumor response?
43 Current Suggested Indications of DEB-TACE Think the advantages - Excellent pharmacokinetics - Less post-embolization syndrome - Better tumor response? Think the limitations first - Not too small ( 2 cm) or not too large tumor (< 5 cm) (large tumor repeated TACE or additional embolization) - Hypervascular/encapsulated tumor - Non-median/central liver location - Can be treated with superselective approach
44 DEB-TACE in Future Advances Relatively large particles (100~300 μm) - Cannot pass through small feeding artery or into portal vein - Limited efficacy in small/early HCC or hypovascular tumor Smaller 40 μm-sized microsphere Permanent embolization particles (PVA-based) - Severe vessel damage - Bile duct complication/limited in repeated TACE or lobar treatment Biodegradable drug-eluting microsphere
45 Summary Drug-eluting beads (DEB) have excellent pharmacokinetics with improving antitumor efficacy. However, DEB-TACE did not demonstrate significant superiority in tumor response or overall survival so far. DEB-TACE has some limitations in clinical practice, related to larger-sized particles and permanent embolic effect. Therefore, DEB-TACE may demonstrate better result than before in controlled indications; intermediate sized, hypervascular, encapsulated, peripherally located, single tumors. Future advanced technology will overcome the limitations of current DEB and may bring superiority of DEB-TACE over conventional TACE.
46 감사합니다.
Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationLocoregional Therapy for Hepatoma
Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish
More informationTips and tricks. Camillo Aliberti, Massimo Tilli
Tips and tricks Camillo Aliberti, Massimo Tilli Unit of Oncological Diagnostic and Interventional Radiology, Delta Hospital AUSL Ferrara, Ferrara Italy camy.ali@libero.it mtilli72@libero.it Intra-arterial
More informationLocoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates
Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses
More informationIn Vivo Behavior of Drug-Eluting Embolics. J. Namur, PhD Archimmed SARL
In Vivo Behavior of Drug-Eluting Embolics J. Namur, PhD Archimmed SARL Julien Namur, Ph.D. Employee: Archimmed SARL Research Grants: BTG, Terumo, Microvention, Merit Medical, Nanobiotix, Covidien, Cardiatis,
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationtreatment options for primary liver malignancies and metastatic disease
State of the art treatment options for primary liver malignancies and metastatic disease Peter Huppert Prof. of Radiology and Neuroradiology Klinikum Darmstadt Certified Vascular and Oncologic Center Disclosure
More informationLiver Directed Therapy for Hepatocellular Carcinoma
Liver Directed Therapy for Hepatocellular Carcinoma Anil K Pillai MD, FRCR, Associate Professor, Department of Radiology UT Houston Health Science Center, Houston, TX, United States. Hepatocellular cancer
More informationIntra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization
Intra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization Department of Radiology, National Cancer Center In Joon Lee Contents Conventional TACE Role of TACE in management
More informationHepatocellular carcinoma: Intra-arterial treatments
Hepatocellular carcinoma: Intra-arterial treatments Irene Bargellini U.O. Radiologia Interventistica Azienda Ospedaliero Universitaria Pisana IRENE BARGELLINI,MD UO RADIOLOGIA INTERVENTISTICA, AZIENDA
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationMULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC
Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY
More informationSIRT for Intermediate and Advanced HCC
Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro
More informationCHEMOEMBOLISATION USING IODIZED OIL(LIPIODOL ) BASED TECHNIQUES
CHEMOEMBOLISATION USING IODIZED OIL(LIPIODOL ) BASED TECHNIQUES Peter Huppert Department of Radiology, Neuroradiology and Nuclear Medicine Klinikum Darmstadt ATH Universities of Frankfurt and Heidelberg/Mannhein
More information100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days
100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,
More informationInterventional Radiologic Treatment of Hepatocellular Carcinoma
Interventional Radiologic Treatment of Hepatocellular Carcinoma Fatih Boyvat Abstract The current treatment modalities for patients with hepatocellular carcinoma are discussed in this review. Hepatocellular
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationHCC RADIOLOGIC DIAGNOSIS
UCSF Transplant 2010 THE BEFORE AND AFTER HEPATOCELLULAR CARCINOMA MANAGEMENT Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation University of California,
More informationRadioembolization: technical aspects
Radioembolization: technical aspects Rita Golfieri Unità Operativa Radiologia Malpighi Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola - Malpighi La sottoscritta dichiara di non aver
More informationLong-term follow-up after conventional transarterial chemoembolization (c-tace) with mitomycin for hepatocellular carcinoma (HCC)
Original Article Long-term follow-up after conventional transarterial chemoembolization (c-tace) with mitomycin for hepatocellular carcinoma (HCC) Ricardo Yamada, Beatriz Bassaco, Stephen Bracewell, Kirkpatrick
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationhqtace The Next Generation in Liver Cancer Treatment
HepaSphere Microspheres Quality Targeted to the tumor Absorbs drug Conforms to the vessel Elutes and embolizes hqtace The Next Generation in Liver Cancer Treatment Quality TACE hqtace The No-Compromise
More informationMDCT findings after hepatic chemoembolization with DC-beads: What the radiologist needs to know
Abdominal Imaging ª Springer Science+Business Media New York 2012 Published online: 10 October 2012 Abdom Imaging (2013) 38:778 784 DOI: 10.1007/s00261-012-9963-6 MDCT findings after hepatic chemoembolization
More informationFeasibility Study of Transcatheter Arterial Chemoembolization with Epirubicin Drug-eluting Beads for Hepatocellular Carcinoma in Japanese Patients
Original Research Feasibility Study of Transcatheter Arterial Chemoembolization with Epirubicin Drug-eluting Beads for Hepatocellular Carcinoma in Japanese Patients 1) Department of Diagnostic Radiology,
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationTransarterial Chemoembolization in Neuroendocrine Liver Metastasis
Transarterial Chemoembolization in Neuroendocrine Liver Metastasis Ricardo D. Garcia-Monaco, MD, PhD, FSIR; Andres Alejandro Kohan, MD From Vascular and Interventional Radiology, Department of Radiology,
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationHamad Alsuhaibani,MD KING FAISAL SPECIALIST HOSPITAL &RESEARCH CENTRE.
Hamad Alsuhaibani,MD KING FAISAL SPECIALIST HOSPITAL &RESEARCH CENTRE. YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA EFFICACY AND SAFETY OF YTTRIUM-90 RADIO- EMBOLIZATION
More information9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES
UCSF Transplant 2018: Pioneering Advances in Transplantation DISCLOSURES Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? I have no relevant commercial interests or relationships to report
More informationHCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation
HCC Imaging and Advances in Locoregional Therapy David S. Kirsch MD Ochsner Clinic Foundation -Nothing to disclose Hepatic Imaging Primary imaging modalities include: US CT MR Angiography Nuclear medicine
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More informationTransarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future
pissn 2287-2728 eissn 2287-285X Review Clinical and Molecular Hepatology 2015;21:344-348 Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and
More informationChemoembolization of Hepatocellular Carcinoma
3 Chemoembolization of Hepatocellular Carcinoma RiccardoLencioni,MD,FSIR,EBIR 1 Pasquale Petruzzi, MD 1 LauraCrocetti,MD,PhD,EBIR 1 1 Division of Diagnostic Imaging and Intervention, Pisa University School
More informationINTRAARTERIAL TREATMENT OF COLORECTAL LIVER METASTASES. Dr. Joan Falcó Interventional Radiology UDIAT. Hospital Universitari Parc Taulí
INTRAARTERIAL TREATMENT OF COLORECTAL LIVER METASTASES Dr. Joan Falcó Interventional Radiology UDIAT. Hospital Universitari Parc Taulí STRATEGIES FOR CRLM LIVER METASTASES Extended indications Resectable
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationHCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)
HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,
More informationResorbable particles: Are they the future?
Resorbable particles: Are they the future? Jafar Golzarian Professor of Radiology & Surgery Director, Division of Interventional Radiology University of Minnesota Why Resorbable? Common sense: Trend Patient
More informationPortal Vein Invasion and the Role of Liver Directed Therapy. Matthew S Johnson MD FSIR Indiana University May 6, 2016
Portal Vein Invasion and the Role of Liver Directed Therapy Matthew S Johnson MD FSIR Indiana University May 6, 2016 Matthew Johnson, M.D., FSIR Stock: Endoshape Consultant/Advisory Board: Bayer, BTG,
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationSIRTEX Lunch Symposium, Cebu, 23 Nov Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong
SIRTEX Lunch Symposium, Cebu, 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong I will not talk on Mechanism of SIRT Data on efficacy of SIRT Epidemiology
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationULTRA FLUID. Lipiodol efficacy & safety. for improved overall survival in HCC. Localization. Vectorization. Visualization. Chemo-Embolization
Ethyl ester of iodized fatty acids of poppy seed oil ULTRA FLUID Lipiodol efficacy & safety 1,2,3,4 for improved overall survival in HCC Localization Endorsed by International HCC Treatment Guidelines
More informationCombination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma
ORIGINAL ARTICLE Korean J Intern Med 2016;31:242-252 Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma Myeong Jun Song 1, Si Hyun Bae 1,
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationGuidelines for SIRT in HCC An Evolution
Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early
More informationRuolo della interventistica per le secondarietà epatiche e di altre sedi
Ruolo della interventistica per le secondarietà epatiche e di altre sedi Giancarlo Bizzarri Dipartimento di Diagnostica per Immagini e Radiologia Interventistica Ospedale Regina Apostolorum, Albano Laziale
More informationState-of-the-art minimally invasive interventions for liver tumors
William Lo, HMS MD/PhD candidate, MS III Gillian Lieberman, MD State-of-the-art minimally invasive interventions for liver tumors William Lo, HMS MD/PhD candidate, MS III Gillian Lieberman, MD
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More informationTreatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center
Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new
More informationLiver metastases: treatment planning. PJ Valette
Liver metastases: treatment planning PJ Valette Liver metastases removal December 2010 April 2011 : after chemotherapy June 2011 : after resection of left lobe mets & portal embol. Sept 2011 : 1 year after
More informationUNIVERSITA DEGLI STUDI DI PISA FACOLTA DI MEDICINA E CHIRURGIA. Scuola di Specializzazione in Radiodiagnostica TESI DI SPECIALIZZAZIONE
UNIVERSITA DEGLI STUDI DI PISA FACOLTA DI MEDICINA E CHIRURGIA Scuola di Specializzazione in Radiodiagnostica TESI DI SPECIALIZZAZIONE ROLE OF TRANSARTERIAL CHEMOEMBOLIZATION AS NEOADJUVANT TREATMENT IN
More informationRADIATION SEGMENTECTOMY. Robert J Lewandowski, MD
RADIATION SEGMENTECTOMY Robert J Lewandowski, MD Robert Lewandowski, M.D. Consultant/Advisory Board: Cook Medical, LLC, Arsenal, BTG International, Boston Scientific Corp., ABK Reference Unlabeled/Unapproved
More informationEPIDEMIOLOGY. Long established risk factors for CCA: hepatobiliaryflukes, PSC, biliary tract cysts, epatolithiasis.
EPIDEMIOLOGY Intrahepatic cholangiocarcinoma(icc) is the second most common (15%) primary liver cancer after hepatocellular carcinoma (HCC), with a rate of about 2.1/100,000 people per year in western
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationSelective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma International Course on THERANOSTICS and MOLECULAR RADIOTHERAPY Brussels, 4 october 2017 Vincent Donckier
More informationHow to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung
How to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung End points in research for solid cancers Overall survival (OS) The most ideal one, but requires long follow-up duration
More informationRegional Therapy for Metastatic Neuroendocrine Tumors. Janette Durham, MD Professor of Radiology University of Colorado School of Medicine
Regional Therapy for Metastatic Neuroendocrine Tumors Janette Durham, MD Professor of Radiology University of Colorado School of Medicine Introduce regional therapy for mnet Arterial therapies Injection
More informationIn- and exclusion criteria
In- and exclusion criteria Kerstin Schütte Department of Gastroenterology, Hepatology and Infectious Diseases University of Magdeburg Overview: Study population Inclusion criteria I - General criteria
More informationAdvances in percutaneous ablation for hepatocellular carcinoma
Advances in percutaneous ablation for hepatocellular carcinoma P. Nahon1,2,3 1 Hepatology, Jean Verdier Hospital, APHP, Bondy, France 2 Paris 13 university, Sorbonne Paris Cité, UFRSMBH, Bobigny, France
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationHepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization
Hepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization JP King PGY2 May 22, 2015 Neuroendocrine Tumor (NET) WHO Classification Location
More informationRole of loco-regional treatment in the medical and surgical management strategy of metastatic colorectal cancer
Role of loco-regional treatment in the medical and surgical management strategy of metastatic colorectal cancer M Ducreux, MD, PhD Gustave Roussy Villejuif, FRANCE M Ducreux is a consultant to Biocompatibles
More informationTranscatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies
Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Policy Number: 8.01.11 Last Review: 6/2018 Origination: 8/2005 Next Review: 6/2019 Policy Blue Cross and Blue
More informationLiver Cancer: Diagnosis and Treatment Options
Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver
More informationFegato le)eratura ed esperienza clinica. A Guarneri
Fegato le)eratura ed esperienza clinica A Guarneri EASL EORTC Clinical Practice GuidelinesJ Hepatology 2012 HEPATOCELLULAR CARCINOMA Classic Radia*on-Induced Liver Disease (RILD) Clinical syndrome of
More informationHOW I DO IT: SIRT for Hepatocellular Carcinoma
HOW I DO IT: SIRT for Hepatocellular Carcinoma Philip Chong-hei KWOK Department of Radiology and Imaging Queen Elizabeth Hospital HONG KONG SAR, CHINA Declaration I have no financial interest to declare
More informationCurrent Treatment Strategies for Hilar and Intrahepatic Cholangiocarcinoma
Current Treatment Strategies for Hilar and Intrahepatic Cholangiocarcinoma Jean-Nicolas Vauthey, MD, FACS Professor of Surgery Chief Hepato-Pancreato-Biliary Section Department of Surgical Oncology Crescent
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationHelping you access curative therapies for liver cancer patients
Metastatic colorectal cancer (mcrc) Helping you access curative therapies for liver cancer patients Biocompatibles Excellence in Interventional Oncology Biocompatibles UK Ltd is a BTG International group
More informationCurrent Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005
Current Treatment of Colorectal Metastases Dr. Thavanathan Surgical Grand Rounds February 1, 2005 25% will have metastases at initial presentation 25-50% 50% will develop metastases later 40% of potentially
More informationStaging & Current treatment of HCC
Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt
More informationOptimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC)
XXVI SETH Congress- 30 November 2017 Optimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) Neil Mehta, MD University of California,
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationOptimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose
The Korean Journal of Hepatology 2011;17:51-60 DOI: 10.3350/kjhep.2011.17.1.51 Original Article Optimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose Robert Martin
More informationdoi: /hepr Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)
bs_bs_banner Hepatology Research 2016; 46: 3 9 doi: 10.1111/hepr.12542 Special Report Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version) Masatoshi Kudo, Kazuomi Ueshima,
More informationFive-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma
Liu et al. BMC Gastroenterology (2018) 18:124 https://doi.org/10.1186/s12876-018-0848-1 RESEARCH ARTICLE Open Access Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization
More informationHepatocellular Carcinoma: Transplantation, Resection or Ablation?
Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Roberto Gedaly MD Chief, Abdominal Transplantation Transplant Service Line University of Kentucky Nothing to disclose Disclosure Objective
More informationTransarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (ctace)
Med Sci Monit, 2011; 17(4): 189-195 PMID: 21455104 WWW.MEDSCIMONIT.COM Clinical Research Received: 2010.08.04 Accepted: 2010.10.31 Published: 2011.04.01 Transarterial Chemoembolization of Child-A hepatocellular
More informationSurgery for hilar cholangiocirconoma
Department of Surgery University Hospital RWTH Aachen Surgery for hilar cholangiocirconoma Ulf Peter Neumann Agenda Operating on the most complex tumor in HBP Surgery Preoperative management Does the patient
More informationEvangelos Chartampilas Bioclinic Hospital Thessaloniki, Greece
Evangelos Chartampilas Bioclinic Hospital Thessaloniki, Greece Hepatospecificcontrast agents Gadobenate dimeglumine (Multihance) Gadoxeticacid (Primovist) 3-5% liver uptake 50% liver uptake Hepatobiliary
More informationTrans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?
Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:
More informationFunctional liver imaging Bernard Van Beers
Functional liver imaging Bernard Van Beers Department of Radiology Beaujon University Hospital Paris Nord Laboratory of Imaging biomarkers UMR 1149 Inserm - University Paris Diderot France Functional imaging
More information8/1/2017. Disclosures. Outline. SAM Imaging Education Course 90Y-Microsphere Therapy: Emerging Trends and Future Directions
SAM Imaging Education Course Y-Microsphere Therapy: Emerging Trends and Future Directions Matt Vanderhoek, PhD Henry Ford Health System, Detroit, MI Vanessa Gates, MS Northwestern University, Chicago,
More informationLatest Developments in the Treatment of Hepatocellular Carcinoma
Latest Developments in the Treatment of Hepatocellular Carcinoma Roniel Cabrera, MD MS Associate Professor of Medicine Director of Hepatology and Medical Director of Liver Transplantation Division of Gastroenterology,
More informationSplenic Trauma Where to Occlude and with what
Splenic Trauma Where to Occlude and with what Trauma session, Thurday May 5, 2016 Pierre GOFFETTE St-Luc University Hospital Brussels Pierre Goffette, M.D. Consultant/Advisory Board: Covidien (Neuro) and
More informationin Hepatocellular Carcinoma
in Hepatocellular Carcinoma The following summarises the key data supporting the use of SIR-Spheres Y-90 resin microspheres in the treatment of primary liver cancer due to hepatocellular carcinoma (HCC):
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More informationVolumetric Functional MRI Criteria for Assessing Tumor Response
Volumetric Functional MRI Criteria for Assessing Tumor Response Ihab R. Kamel, M.D., Ph.D. ikamel@jhmi.edu Associate Professor of Radiology and Oncology Clinical Director, MRI Department of Radiology Johns
More informationRadioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases
Radioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases Pr Francesco Giammarile CHLS Lyon Faculté de Lyon Sud «Aut tace aut loquere meliora silentio» Malignant
More informationPolyvinyl Alcohol Embolization Adjuvant to Oily Chemoembolization in Advanced Hepatocellular Carcinoma with Arterioportal Shunts
Polyvinyl Alcohol Embolization Adjuvant to Oily Chemoembolization in Advanced Hepatocellular Carcinoma with Arterioportal Shunts Yeo Ju Kim, MD 1 Hae Giu Lee, MD 1 Jeong Mi Park, MD 2 Yeon Soo Lim, MD
More informationSBRT and hypofractionated RT for HCC patients with varying degrees of hepatic impairment
SBRT and hypofractionated RT for HCC patients with varying degrees of hepatic impairment Nima Nabavizadeh, MD Assistant Professor Division Leader Hematologic Malignancies Co-division Leader Gastrointestinal
More informationTherapeutic Response Assessment and Endpoints in HCC
APASL HCC Conference, 2013 Cebu Therapeutic Response Assessment and Endpoints in HCC Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Surgery Chief of Hepatobiliary and Pancreatic Surgery The University
More informationBasics of Angiographic Interpretation Analysis of Angiography
Basics of Angiographic Interpretation Analysis of Angiography Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Seoul, Korea What made us nervous Supervisors Stent Contrast
More informationUPDATES IN INTRACRANIAL INTERVENTION Jordan Taylor DO Metro Health Neurology 2015
UPDATES IN INTRACRANIAL INTERVENTION Jordan Taylor DO Metro Health Neurology 2015 NEW STUDIES FOR 2015 MR CLEAN ESCAPE EXTEND-IA REVASCAT SWIFT PRIME RECOGNIZED LIMITATIONS IV Alteplase proven benefit
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationCAPGAN th Scientific Meeting of Commonwealth Association of Paediatric, Gastroenterology and Nutrition 2-4 October 2015 : New Delhi, India
CAPGAN2015 14 th Scientific Meeting of Commonwealth Association of Paediatric, Gastroenterology and Nutrition 2-4 October 2015 : New Delhi, India ABSTRACT FORM Abstract Category: Oral Poster 1. GASTROENTEROLOGY
More informationApproaches to type II Endoleaks: Transcaval, transarterial, translumbar. Saher Sabri,MD University of Virginia
Approaches to type II Endoleaks: Transcaval, transarterial, translumbar Saher Sabri,MD University of Virginia Saher Sabri, M.D. Speakers Bureau: W.L.Gore & Associates, Abbott Type 2 Endoleaks after EVAR
More information